C. diff Treatment and Prevention: Antibiotics, FMT, and Infection Control

Getting rid of C. diff is harder than it sounds. The very antibiotics doctors use to treat it can also feed it, and the infection has an uncomfortable habit of coming back — sometimes two or three times — after a course of treatment that appeared to work. This hub covers everything from the first-line antibiotic choices and how severity determines which drug you get, through to fecal microbiota transplantation (FMT) for people stuck in a cycle of recurrence, and the infection control measures that keep C. diff from spreading to other patients or family members. Understanding these options helps you have a more informed conversation with your care team and know what questions to ask when a relapse occurs.

Antibiotic Treatment

Oral vancomycin, fidaxomicin, bezlotoxumab, and the end of metronidazole as first-line therapy.

Fecal Transplant

FMT for recurrent CDI — 90%+ success rate by restoring a healthy gut microbiome.

Infection Control

Soap not alcohol gel, bleach cleaning, contact precautions, and antibiotic stewardship.

Symptoms & Overview

Why C. diff strikes after antibiotics and what the infection feels like.

  1. Stop the Offending Antibiotic First
  2. Antibiotic Choice by Severity
  3. Why Metronidazole Is No Longer First-Line
  4. Preventing Recurrence
  5. Fecal Microbiota Transplantation Overview
  6. Infection Control in Hospitals and at Home
  7. Antibiotic Stewardship and Your Personal Role
  8. Probiotics and Diet During and After Treatment
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Stop the Offending Antibiotic First

The single most important step when C. diff is diagnosed is to discontinue — or at least narrow — whatever antibiotic triggered the infection. Broad-spectrum antibiotics devastate the gut's commensal bacteria, removing the ecological competition that normally keeps C. diff at bay. When you remove that competition, C. diff germinates from its nearly indestructible spores and begins producing toxins.

In mild to moderate CDI, simply stopping the causative antibiotic allows somewhere between 15 and 25 percent of cases to resolve on their own without any specific anti-CDI drug. That may not sound like a lot, but for a patient on an antibiotic they no longer need for their original infection, stopping can be all the treatment required. The 2021 IDSA/SHEA guidelines recommend this as the first consideration before prescribing vancomycin or fidaxomicin.

When stopping is not medically possible — for example, someone in an ICU being treated for a life-threatening gram-negative bacteremia — the goal shifts to choosing the narrowest-spectrum antibiotic that will still treat the underlying infection. Carbapenems, fluoroquinolones, and third-generation cephalosporins carry the highest risk for CDI; switching to a targeted narrow-spectrum agent like piperacillin-tazobactam or even a beta-lactam with a narrow coverage profile can reduce ongoing damage to the gut microbiome while the CDI is simultaneously treated.

The length of time on the causative antibiotic matters too. Patients who received only one or two doses before CDI was suspected have far less gut dysbiosis than someone who has been on broad-spectrum coverage for three weeks. Stopping earlier generally correlates with easier CDI resolution.

Antibiotic Choice by Severity

The 2021 IDSA/SHEA Focused Update stratifies CDI treatment by severity, and the antibiotic choice follows directly from that stratification.

Non-severe CDI is defined as white blood cell count below 15,000 cells/mL and serum creatinine below 1.5 mg/dL. For non-severe CDI, fidaxomicin 200 mg orally twice daily for 10 days is the preferred first-line agent due to lower recurrence rates compared to vancomycin. If fidaxomicin is unavailable or cost-prohibitive, oral vancomycin 125 mg four times daily for 10 days is the standard alternative. Both achieve high concentrations in the colon while being poorly absorbed systemically — exactly the pharmacokinetic profile needed to kill C. diff in its home territory.

Severe CDI is defined as WBC at or above 15,000 cells/mL or creatinine at or above 1.5 mg/dL. For severe disease, oral vancomycin 125 mg four times daily for 10 days is recommended. Fidaxomicin is an acceptable alternative in severe CDI as well.

Fulminant CDI — previously called complicated or severe-complicated CDI — involves hypotension, shock, ileus, or toxic megacolon. In fulminant disease, the ileus means oral drugs may not reach the colon effectively. The recommended regimen is high-dose oral vancomycin (500 mg four times daily) plus intravenous metronidazole 500 mg every eight hours. If ileus is present, vancomycin enemas (500 mg in 100 mL saline every six hours via rectal catheter) are added so the drug can reach the distal colon directly. Early surgical consultation is essential in fulminant disease because some patients need subtotal colectomy or a diverting loop ileostomy to survive.

The fidaxomicin advantage comes from a narrower spectrum of activity — it spares Bacteroides and most other colonocyte-protective anaerobes that vancomycin kills, allowing the normal gut flora to begin recovering sooner and reducing the ecological vacuum that allows C. diff to re-germinate after treatment ends.

Why Metronidazole Is No Longer First-Line

For decades, oral metronidazole was the standard first-line treatment for mild to moderate CDI. It was cheap, widely available, and appeared to work. Then comparative trials and real-world data exposed its limitations: metronidazole reaches the colon primarily through the bloodstream (it is well-absorbed orally), so colonic concentrations are dependent on mucosal inflammation. As the inflammation resolves — which is what you want — drug concentrations in the colon fall, potentially leaving surviving spores and vegetative cells at sub-therapeutic drug levels.

Clinical trials demonstrated that vancomycin outperformed metronidazole for severe CDI in terms of cure rates and mortality. Fidaxomicin then outperformed vancomycin for recurrence rates in non-severe CDI. By 2017–2021, guidelines in the United States and Europe converged on metronidazole being acceptable only when fidaxomicin and vancomycin are truly unavailable, and even then only for non-severe CDI in patients at low risk of recurrence.

Metronidazole remains a component of fulminant CDI treatment — given intravenously, it reaches the colon via inflamed mucosa even when the bowel is paralyzed — but it has been removed from first-line status for initial non-severe and severe disease. Patients who were successfully treated with metronidazole years ago and had no recurrence were probably helped by stopping the causative antibiotic just as much as by the drug itself; for patients who did recur on metronidazole, it is now understood that a vancomycin or fidaxomicin course would likely have been more effective.

Preventing Recurrence

Recurrence is the defining challenge of C. diff management. After a first episode treated with vancomycin, approximately 20 to 30 percent of patients relapse within eight weeks. After a second episode, the recurrence rate climbs to 40 to 65 percent. Each relapse further depletes and distorts the gut microbiome, making the next episode more likely. Breaking this cycle requires both treating the active infection and restoring the ecological conditions that resist C. diff re-establishment.

Bezlotoxumab (Zinplava) is a monoclonal antibody directed against C. diff toxin B. It is given as a single intravenous infusion (10 mg/kg) during — not instead of — the antibiotic course, and it significantly reduces recurrence rates in high-risk patients. High-risk is defined as age 65 or older, immunocompromised status, severe CDI, or one or more prior CDI episodes. The MODIFY I and II trials showed that bezlotoxumab reduced recurrence from about 26 percent to 17 percent compared to placebo, a meaningful reduction given how difficult recurrent CDI is to treat. It does not replace the antibiotic; it works alongside it.

Tapered and pulsed vancomycin is the standard approach for a first recurrence. Rather than a 10-day flat course, a common regimen is: vancomycin 125 mg four times daily for 10–14 days, then 125 mg twice daily for 7 days, then 125 mg once daily for 7 days, then 125 mg every 2–3 days for 2–8 weeks. The taper gives the gut microbiome time to partially reconstitute between doses while keeping C. diff suppressed; the pulse phase takes advantage of the fact that C. diff spores are not killed by vancomycin — only vegetative cells are — so pulsing targets each new wave of spore germination.

Rifaximin chaser involves following a vancomycin course with rifaximin 400 mg three times daily for 20 days. Rifaximin has poor bioavailability systemically but high colonic concentrations; the theory is that residual C. diff in the "chaser" window is further suppressed while the microbiome recovers. Evidence from small trials is promising but not yet definitive.

For a second or subsequent recurrence, FMT is now the recommended intervention — see the overview below and the dedicated FMT sub-article for full details.

Fecal Microbiota Transplantation Overview

FMT is the transfer of processed stool from a healthy, screened donor into the gut of a patient with recurrent CDI, with the goal of restoring a diverse, protective microbiome. It has a success rate of 85 to 92 percent for recurrent CDI — dramatically higher than repeated antibiotic courses — and is now recommended by IDSA/SHEA guidelines for patients who have experienced two or more CDI recurrences.

The mechanism is ecological, not pharmacological. A healthy donor's microbiome contains hundreds of commensal species that compete with C. diff for nutrients, physical niches in the mucus layer, and bile acid pools that regulate C. diff spore germination. Transplanting this ecosystem re-establishes the competition that antibiotics originally destroyed. Within weeks, the recipient's gut microbiome begins to resemble the donor's.

Two FDA-approved microbiome-based products are now available, avoiding the regulatory complexities of using individual donors:

Traditional FMT via colonoscopy or nasojejunal tube is still performed in clinical settings, particularly for severe or complex cases, using fresh or frozen material from rigorously screened donors. The FDA has established oversight frameworks that require institutions to follow specific donor screening protocols.

For full details on indications, donor screening, procedural approaches, what to expect, costs, and insurance coverage, see the dedicated Fecal Microbiota Transplant sub-article.

Infection Control in Hospitals and at Home

C. diff spreads through the fecal-oral route via spores that are extraordinarily resistant to standard disinfection. Understanding the right decontamination tools is essential whether you are a patient in a hospital, a visitor, or a caregiver at home.

The single most important point: alcohol-based hand sanitizers do not kill C. diff spores. The alcohol denatures proteins in vegetative bacteria but cannot penetrate the thick protein coat of a spore. Soap and water — specifically the mechanical scrubbing action — physically removes spores from hands and carries them down the drain. Every clinical guideline mandates soap-and-water handwashing over alcohol gel for C. diff contact precautions.

Environmental decontamination requires sporicidal agents. Hypochlorite (bleach) solutions at 1:10 dilution kill C. diff spores on hard surfaces; standard quaternary ammonium ("quat") disinfectants commonly used in hospitals do not. Studies have shown that switching from quat-based to bleach-based environmental cleaning in CDI-endemic hospital units reduces CDI rates significantly. At home, a 1:10 dilution of household bleach applied to bathrooms, toilet handles, faucets, and frequently touched surfaces is appropriate when a household member is actively infected.

Contact precautions in hospitals mean gowns and gloves for anyone entering the room of a CDI patient, dedicated equipment that stays in the room (blood pressure cuffs, stethoscopes), and private rooms wherever possible. Spores can survive on dry surfaces for months, so thorough terminal cleaning of the room after discharge is critical.

At home, isolating bathroom use (or rigorous bleach cleaning between uses), separate towels, and dedicated bedding for the patient reduces household transmission risk. C. diff is not spread through the air or by casual contact — it requires ingestion of spores, which in practice means contaminated hands or surfaces touching the mouth.

For complete guidance on hospital precautions, home care protocols, and how to communicate your CDI history to care providers, see the Infection Control and Prevention sub-article.

Antibiotic Stewardship and Your Personal Role

Antibiotic stewardship programs at hospitals and clinics are one of the most effective tools for reducing CDI rates at a population level. These programs use algorithms, pharmacist review, and prescriber feedback to ensure antibiotics are prescribed only when indicated, at the appropriate dose and duration, and with the narrowest spectrum needed. Studies consistently show that implementing formal stewardship programs reduces hospital-acquired CDI rates by 20 to 50 percent.

At the individual patient level, stewardship translates into practical decisions you can make:

The Lessa et al. NEJM 2015 study estimated that C. diff caused approximately 453,000 infections and 29,300 deaths in the United States in a single year — figures that underscore why stewardship at both institutional and individual levels is a genuine public health imperative, not just a precaution for medically fragile patients.

Probiotics and Diet During and After Treatment

The evidence for probiotics in CDI prevention and treatment is mixed, but the area with the most support is primary prevention in patients receiving antibiotics. A 2022 Cochrane review found that probiotics — particularly Lactobacillus and Saccharomyces boulardii strains — reduced the risk of developing CDI in people taking antibiotics, though the evidence was graded as moderate quality. IDSA/SHEA 2021 guidelines do not include a strong recommendation for probiotics as CDI treatment, but note that evidence is insufficient to recommend against them in patients who wish to use them.

Importantly, probiotics are not a substitute for antibiotic treatment in active CDI. The bacteria in probiotic supplements are not the same as the hundreds of species transferred in FMT; they are a small ecological intervention on a much larger problem.

Diet during CDI treatment should focus on tolerability: low-fiber foods during acute diarrhea (white rice, toast, cooked vegetables, bananas) to reduce bowel stimulation, with gradual reintroduction of fiber-rich whole foods as symptoms resolve. There is no special CDI diet validated in clinical trials, but several practical points hold: staying well hydrated is essential because CDI diarrhea can cause significant fluid losses; avoiding dairy during active diarrhea may reduce discomfort if lactase activity is temporarily reduced by gut inflammation; and gradually reintroducing fermented foods (yogurt with live cultures, kefir, sauerkraut) after the antibiotic course ends may support microbiome reconstitution, though the evidence is preliminary.

Avoiding proton pump inhibitors (PPIs) where possible is worth discussing with your provider. Several observational studies have found an association between PPI use and higher CDI incidence and recurrence risk, likely because gastric acid is one barrier to C. diff spore germination in the upper gut. If PPIs are being used for symptomatic relief rather than a firm acid-related diagnosis, a trial of de-escalation after CDI resolution may reduce recurrence risk.

Key Research Papers

The following studies form the evidence base for current CDI treatment guidelines. All citations include PMID links to PubMed for direct access to abstracts and full papers.

  1. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73(5):e1029-e1044. PMID 34164374
  2. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415. PMID 23323867
  3. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med. 2011;364(5):422-431. PMID 21288078
  4. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-289. PMID 22321770
  5. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305-317. PMID 28121498
  6. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile. N Engl J Med. 2022;386(3):220-229. PMID 35045228
  7. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2016;214(2):173-181. PMID 26908744
  8. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313(17):1719-1727. PMID 25942722
  9. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478-498. PMID 23439232
  10. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-834. PMID 25714160

PubMed searches for further reading:

  1. Clostridioides difficile treatment guidelines
  2. Fidaxomicin vs vancomycin CDI recurrence
  3. Fecal microbiota transplant recurrent C. difficile
  4. Bezlotoxumab prevention CDI recurrence
  5. Antibiotic stewardship Clostridioides difficile prevention

Connections

Back to Table of Contents